Liquidia Corp. (LQDA)
70.28
+1.66
(+2.41%)
USD |
NASDAQ |
Aug 24, 16:00
70.28
0.00 (0.00%)
After-Hours: 20:00
Liquidia Gross Profit Margin (Quarterly) : 93.10% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.10% |
| March 31, 2026 | 90.86% |
| December 31, 2025 | 92.09% |
| September 30, 2025 | 93.65% |
| June 30, 2025 | 82.14% |
| March 31, 2025 | 40.13% |
| December 31, 2024 | 42.68% |
| September 30, 2024 | 57.85% |
| June 30, 2024 | 51.54% |
| March 31, 2024 | 40.92% |
| December 31, 2023 | 71.95% |
| September 30, 2023 | 73.63% |
| June 30, 2023 | 79.71% |
| March 31, 2023 | 78.77% |
| December 31, 2022 | 76.64% |
| September 30, 2022 | 48.18% |
| June 30, 2022 | 71.13% |
| March 31, 2022 | 68.67% |
| December 31, 2021 | 63.74% |
| Date | Value |
|---|---|
| September 30, 2021 | 34.02% |
| June 30, 2021 | 42.32% |
| March 31, 2021 | 35.95% |
| December 31, 2020 | -30.50% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 82.34% |
| March 31, 2019 | |
| December 31, 2018 | 28.20% |
| September 30, 2018 | -141.4% |
| June 30, 2018 | 52.50% |
| March 31, 2018 | 62.00% |
| December 31, 2017 | 81.41% |
| September 30, 2017 | 83.17% |
| June 30, 2017 | 84.64% |
| March 31, 2017 | 81.52% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Indivior Pharmaceuticals, Inc. | 85.42% |
| Harmony Biosciences Holdings, Inc. | 73.53% |
| Johnson & Johnson | 68.73% |
| Amneal Pharmaceuticals, Inc. | 42.01% |
| Corcept Therapeutics, Inc. | 98.41% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 179.7% |
| Return on Assets | 38.75% |
| Return on Invested Capital | 53.03% |
| Profit Margin (Quarterly) | 43.52% |
| Operating Margin (Quarterly) | 49.81% |
| Return on Net Operating Assets | 127.3% |